
Carla Marie (Lichtenberger) Nester MD MSA, FASN
Professor of Internal Medicine and Pediatrics, University Iowa,Carver College of Medicine
Join to View Full Profile
285 Newton Road5294 CBRBIowa City, IA 52241
Phone+1 319-335-2214
Fax+1 319-384-9616
Dr. Nester is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of North Carolina HospitalsFellowship, Nephrology, 2003 - 2007
- University of North Carolina HospitalsFellowship, Pediatric Nephrology, 2003 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine/Pediatrics, 1998 - 2002
- Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
- IA State Medical License 2007 - 2025
- NC State Medical License 1999 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Nephrology
Publications & Presentations
PubMed
- The authors reply.Marina Vivarelli, Carla M Nester
Kidney International. 2025-05-01 - Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.Dorey A Glenn, Ashley W Carver, Margaret E Helmuth, Abigail R Smith, Richard A Lafayette
Clinical Journal of the American Society of Nephrology. 2025-04-10 - Clinical Decision-Making About Immunosuppressive Treatment in Focal Segmental Glomerulosclerosis.Brooke Blazius, Jonathan P Troost, Jeffrey B Kopp, Rulan S Parekh, Brenda Gillespie
Kidney Medicine. 2025-04-01
Press Mentions
- First Drug Approved for Ultra-Rare Kidney DiseaseMarch 21st, 2025
- Novartis Oral Fabhalta Secures USFDA Okay for Adults with C3 GlomerulopathyMarch 20th, 2025
- Novartis Receives Third FDA Approval for Oral Fabhalta® (Iptacopan) – the First and Only Treatment Approved in C3 Glomerulopathy (C3G)March 20th, 2025
- Join now to see all
Grant Support
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: